Biochemical tests for the diagnosis of high risk of preterm birth


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

According to the results of clinical studies published in the English and Russian literature in open databases the author has determined the significance and effectiveness of biochemical tests for the diagnosis of preterm birth. The definition of PAMG-1 for the diagnosis of preterm labor has sensitivity values of 84%, specificity is 95%, positive predictive value is 77% and negative prognosis is 97% and is a more reliable method than determining fFN, fPSIFR-1 or measuring cervical length and is associated with a reduction in f inancial costs. The use of the test kit for determining PAMG-1 is the most effective in comparison with other methods and allows to avoiding incorrect diagnosis and unnecessary hospitalization.

Full Text

Restricted Access

About the authors

Galina B. Dikke

Peoples' Friendship University of Russia

Email: galadikke@yandex.ru
MD, Professor of the Department of Obstetrics, Gynecology and Reproductive Medicine, Faculty of Postgraduate Education of Medical Workers of the Medical Institute

References

  1. Фаткуллин И.Ф., Ахметгалиев А.Р., Мунавирова А.А., Фаткуллин Ф.И. Преимущества применения диагностической экспресс-тест-системы для определения плацентарного а-микроглобулина-1 в цервикальном содержимом для идентификации начавшихся/угрожающих преждевременных родов. Акушерство и гинекология. 2018; 1: 62-8. https://dx.doi.org/10.18565/ aig.2018.1.62-68
  2. Mella M.T., Berghella V. Prediction of preterm birth: cervical sonography. Rev. Semin. Perinatol. 2009; 33(5): 317-24.
  3. Berghella V., Hayes E., Visintine J., Baxter J.K. Fetal fibronectin testing for reducing the risk of preterm birth. Cochrane Database Syst. Rev. 2008; (4): CD006843. Available at: http://cochranelibrary-wiley.com/
  4. Conde-Agudelo A., Romero R. Cervicovaginal fetal fibronectin for the prediction of spontaneous preterm birth in multiple pregnancy: a systematic review and meta-analysis. J. Matern. Fetal Neonatal Med. 2010; 23(12): 1365-76.
  5. Berghella V., Saccone G. Fetal fibronectin testing for prevention of preterm birth in singleton pregnancies with threatened preterm labor: a systematic review and meta-analysis of randomized controlled trials. Am. J. Obstet. Gynecol. 2016; 215(4): 431-8.
  6. Ruma M.S., Bittner K.C., Soh C.B. Current perspectives on the use of fetal fibronectin testing in preterm labor diagnosis and management. Am. J. Manag. Care. 2017; 23(Suppl.19): S356-62.
  7. Khambay H., Bolt L.A., Chandiramani M., De Greeff A., Filmer J.E., Shennan A.H. The Actim Partus test to predict pre-term birth in asymptomatic high-risk women. J. Obstet. Gynaecol. 2012; 32(2): 132-4.
  8. Fuchs F., Houllier M., Leparco., Guyot A., Senat M.V., Fernandez H. Performance of cervical phIGFBP-1 test alone or combined with short cervical length to predict spontaneous preterm birth in symptomatic women. Sci. Rep. 2017; 7(1): 10856.
  9. Di Renzo G.C., Cabero Roura L., Facchinetti F., Helmer H., Hubinont C., Jacobsson B. et al. Preterm labor and birth management: Recommendations from the European Association of Perinatal Medicine. J. Matern. Fetal Neonatal Med. 2017; 30(17): 2011-30. Available at: https://www.tandfonline.com/
  10. Bolotskikh V., Borisova V. Combined value of placental alpha microglobulin-1 detection and cervical length via transvaginal ultrasound in the diagnosis of preterm labor in symptomatic patients. J. Obstet. Gynaecol. Res. 2017; 43(8): 1263-9.
  11. Lotfi G., Faraz S., Nasir R., Somini S., Abdeldayem R.M., Koratkar R. et al. Comparison of the effectiveness of a PAMG-1 test and standard clinical assessment in the prediction of preterm birth and reduction of unnecessary hospital admissions. J. Matern. Fetal Neonatal Med. 2017; October 26: 1-5.
  12. Melchor J.C., Navas H., Marcos M., Iza A., de Diego M., Rando D. et al. Retrospective cohort study of PAMG-1 and fetal fibronectin test performance in assessing spontaneous preterm birth risk in symptomatic women attending an emergency obstetrical unit. Ultrasound Obstet. Gynecol. 2017; Aug 29. Available at: https://www.ncbi.nlm.nih.gov/
  13. Hadzi-Lega M., Maier J.T., Helmer H., Hellmeyer L., Markova A.D., Poposka A. Comparison of PAMG-1 and phIGFBP-1 tests for the prediction of preterm delivery in patients with preterm labor. Open J. Obstet. Gynecol. 2017; 7(3): 358-68.
  14. Ravi M., Beljorie M., El Masry K. Evaluation of the quantitative fetal fibronectin test and PAMG-1 test for the prediction of spontaneous preterm birth in patients with signs and symptoms suggestive of preterm labor. J. Matern. Fetal Neonatal Med. 2018; May 28: 1-6.
  15. Melchor J.C., Khalil A., Wing D., Schleussner E., Surbek D. Prediction of preterm delivery in symptomatic women using placental alpha-microglobulin-1, fetal fibronectin and phosphorylated insulin-like growth factor-binding protein-1 tests: systematic review and meta-analysis stratified by risk. Ultrasound Obstet. Gynecol. 2018; Jun 19. doi: 10.1002/uog.19119. [Epub ahead of print]. Available at: https://www.ncbi.nlm.nih.gov/
  16. Di Fabrizio L., Giardina I., Cetin I., Di Tommaso M., Ciavattini A., Locci M. et al. New methods for prediction of preterm birth: the PAMG-1 test. Minerva Ginecol. 2018; May 31. doi: 10.23736/S0026-4784.18.04243-0. [Epub ahead of print]. Available at: https://www.ncbi.nlm.nih.gov/
  17. Van Holsbeke C., Dam K., Staelens A., Mesens T., Corremans A. Comparison of the fetal fibronectin (Rapid fFN) and placental alpha microglobulin-1 (PartoSure) tests for predicting imminent spontaneous preterm birth. Ultrasound Obstet. Gynecol. 2016; 48(1): 84.
  18. Петрунин Д.Д., Грязнова И.М., Петрунина Ю.А., Татаринов Ю.С. Сравнение иммунохимических и физико-химических характеристик хорионических α1- и α2-микроглобулинов плаценты человека. Бюлл. эксперим. биологии и медицины. 1978; 85(5): 658-61.
  19. Fuchs B.B., Boltovskaya M.N., Zaraiskii E.I., Nazimova S.V. Monoclonal antibodies against placental alpha-1-microglobulin (PAMG-1) Int. J. Immunopharmacol. 1991; 13(6): 793.
  20. Sukchaya K., Phupong V. Comparative study of positive rate of placental alpha-microglobulin-1 test in pre-term pregnant women with and without uterine contraction. J. Obstet. Gynaecol. 2013; 33(6): 566-8.
  21. Rosen S.W. New placental proteins: chemistry, physiology and clinical use. Placenta. 1986; 7(6): 575-94.
  22. Петрунин Д.Д., Грязнова И.М., Петрунина Ю.П., Татаринов Ю.С. Иммунологическая идентификация хорионического α1-глобулина плаценты человека и его содержание в амниотической жидкости. Акушерство и гинекология. 1977; 1: 64-5.
  23. Lee S.M., Romero R., Park J.W., Kim S.M., Park C.W., Korzeniewski S.J. et al. The clinical significance of a positive Amnisure test (TM) in women with preterm labour and intact membranes. J. Matern. Fetal Neonatal Med. 2012; 25(9): 1690-8.
  24. U.S. Food and Drug Administration. Medical Devices. PartoSure Test -P160052. Last Updated: 04/30/2018. Available at: https://www.fda.gov/
  25. Nikolova T., Bayev O., Nikolova N., Di Renzo G.C. Evaluation of a novel placental alpha microglobulin-1 (PAMG-1) test to predict spontaneous preterm delivery. J. Perinat. Med. 2014; 42(4): 473-7.
  26. Ehsanipoor R.M., Swank M.L., Jwa S.C., Wing D.A., Tarabulsi G., Blakemore K.J. lacental a-microglobulin-1 in vaginal secretions of women with evidence of preterm labor. Am. J. Perinatol. 2016; 33(2): 208-13.
  27. Белоцерковцева Л.Д., Коваленко Л.В., Иванников С.Е., Мирзоева Г.Т. Возможности ранней диагностики цервикальной недостаточности для профилактики сверхранних преждевременных родов. Вестник Новгородского государственного университета им. Ярослава Мудрого. 2015; 2: 117-23.
  28. Ахметгалиев А.Р., Фаткуллин И.Ф. Мунавирова А.А., Фаткуллин Ф.И. Алгоритм идентификации угрозы преждевременных родов. Казанский медицинский журнал. 2017; 1: 132-6.
  29. Болотских В.М., Борисова В.Ю. Роль определения биохимических тестов и цервикометрии в диагностике угрожающих преждевременных родов. Акушерство и гинекология. 2015; 2: 94-8.
  30. PartoSure Test. Placental alpha microglobulin-1 immunoassay kit. Instructions for in vitro diagnostic use only. Available at: https://www.accessdata.fda.gov/

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies